Oral minoxidil for late alopecia in cancer survivors
- PMID: 39097564
- DOI: 10.1007/s10549-024-07440-5
Oral minoxidil for late alopecia in cancer survivors
Abstract
Purpose: Late alopecia, defined as incomplete hair regrowth > 6 months following cytotoxic chemotherapy or > 6 months from initiation of endocrine therapy, negatively impacts quality of life and may affect dose intensity of adjuvant therapy. This study investigates the effect of oral minoxidil in women with chemotherapy and/or endocrine therapy-induced late alopecia.
Methods: The rate of clinical response was assessed by standardized photography and quantitated with trichoscopy.
Results: Two hundred and sixteen patients (mean age 57.8 ± 13.7) were included. The most common cancer diagnosis was breast, in 170 patients (79.1%). Alopecia developed after chemotherapy in 31 (14.4%) patients, endocrine monotherapy in 65 (30.1%) patients, and chemotherapy followed by endocrine therapy in 120 (55.6%) patients. In 119 patients, standardized photography assessments were used to determine clinical change in alopecia after a median of 105 (IQR = 70) days on oral minoxidil and revealed improvement in 88 (74%) patients. Forty-two patients received quantitative trichoscopic assessments at baseline and at follow-up after a median of 91 (IQR = 126) days on oral minoxidil. Patients had clinically and statistically significant increases in frontal hair shaft density (from 124.2 hairs/cm2 at initial to 153.2 hairs/cm2 at follow-up assessment, p = 0.008) and occipital shaft density (from 100.3 hairs/cm2 at initial to 123.5 hairs/cm2 at follow-up assessment. p = 0.004). No patients discontinued oral minoxidil due to adverse events.
Conclusions: Overall, oral minoxidil was well tolerated by patients and may benefit both frontal and occipital late alopecia in cancer survivors treated with cytotoxic and/or endocrine therapy by increasing hair shaft and follicle density.
Keywords: Adverse events; Alopecia; Breast cancer; Chemotherapy; Endocrine; Minoxidil.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708 - DOI - PubMed
-
- Freites-Martinez A, Shapiro J, Goldfarb S et al (2019) Hair disorders in patients with cancer. J Am Acad Dermatol 80(5):1179–1196. https://doi.org/10.1016/j.jaad.2018.03.055 - DOI - PubMed
-
- Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269. https://doi.org/10.1200/jco.2013.54.2258 - DOI - PubMed - PMC
-
- Freites-Martinez A, Shapiro J, van den Hurk C et al (2019) Hair disorders in cancer survivors. J Am Acad Dermatol 80(5):1199–1213. https://doi.org/10.1016/j.jaad.2018.03.056 - DOI - PubMed
-
- Saggar V, Wu S, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126–1134. https://doi.org/10.1634/theoncologist.2013-0193 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical